PubMed Health⌕ Search

PubMed · 8819178

Challenge interval determines tachyphylaxis to aerosolized LTD4.

Abstract

Leukotrienes (LK) play an important role in the inflammatory response found in the asthmatic airway and it is therefore of interest to explore the clinical value of agents which can either block the effect or inhibit the synthesis of leukotrienes. If tachyphylaxis does not develop, repeated LTD4 challenges can be used for dose ranging studies. Tachyphylaxis has been observed when LTD4 challenge intervals are kept below 1 h, but the effect of prolonging the interval is uncertain. The aim of this study was therefore to investigate the interval between LTD4 challenges necessary to avoid development of tachyphylaxis. Ten stable adult asthmatics with moderate asthma were challenged seven times: a screening day to secure responsiveness to LTD4, two challenges on three separate days with an interval of 2, 4 and 6 h, respectively. No significant differences between mean PC20-LTD4 values (P > 0.5) was found. It was concluded that tachyphylaxis to repeated LTD4 challenges of asthmatics does not develop when challenge intervals are prolonged above 2 h.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Madsen, L Frølund, C S Ulrik. 1995. Challenge interval determines tachyphylaxis to aerosolized LTD4.. https://doi.org/10.1006/pulp.1995.1033

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗